{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:44:55Z","timestamp":1792107895682,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40266-026-01332-7","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T15:06:21Z","timestamp":1788707181000},"page":"921-931","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Adherence Trajectories of First-Line Nucleotide Analogues among US Older Adults with Chronic Hepatitis B"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4850-9215","authenticated-orcid":false,"given":"Javeria","family":"Khalid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5353-2324","authenticated-orcid":false,"given":"Prasun Kumar","family":"Jalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieni","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8033-3988","authenticated-orcid":false,"given":"Xi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2310-901X","authenticated-orcid":false,"given":"Rajender R.","family":"Aparasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"issue":"1","key":"1332_CR1","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cgh.2019.05.053","volume":"18","author":"C-W Peng","year":"2020","unstructured":"Peng C-W, Jeng W-J. Understanding more about hepatitis flare in chronic hepatitis B patients. Clin Gastroenterol Hepatol. 2020;18(1):266\u20137.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1332_CR2","unstructured":"Centers for Disease Control and Prevention. Hepatitis B surveillance [Internet]. 2022 Viral Hepatitis Surveillance Report. 2024 Apr 4 [cited 2024 Nov 20]; Available from: https:\/\/www.cdc.gov\/hepatitis\/statistics\/2022surveillance\/hepatitis-b.htm"},{"key":"1332_CR3","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7201a1","author":"EE Conners","year":"2023","unstructured":"Conners EE. Screening and testing for hepatitis B virus infection: CDC recommendations\u2014United States, 2023. MMWR Recomm Rep. 2023. https:\/\/doi.org\/10.15585\/mmwr.rr7201a1.","journal-title":"MMWR Recomm Rep"},{"key":"1332_CR4","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6701a1","author":"S Schillie","year":"2018","unstructured":"Schillie S. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018. https:\/\/doi.org\/10.15585\/mmwr.rr6701a1.","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"1332_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","volume":"68","author":"H-Y Chen","year":"2019","unstructured":"Chen H-Y, Shen D-T, Ji D-Z, Han P-C, Zhang W-M, Ma J-F, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019;68(3):512\u201321.","journal-title":"Gut"},{"issue":"1","key":"1332_CR6","first-page":"14","volume":"31","author":"MA Corcorran","year":"2023","unstructured":"Corcorran MA, Kim HN. Chronic hepatitis B and HIV coinfection. Top Antiviral Med. 2023;31(1):14.","journal-title":"Top Antiviral Med."},{"issue":"3","key":"1332_CR7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.14218\/JCTH.2018.00016","volume":"6","author":"MG Mavilia","year":"2018","unstructured":"Mavilia MG, Wu GY. HBV-HCV coinfection: viral interactions, management, and viral reactivation. J Clin Transl Hepatol. 2018;6(3):296.","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"1332_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2024.101589","volume":"30","author":"S Hong","year":"2025","unstructured":"Hong S, Hao Y, Sun L, Li P, Yang J, Zhang F, et al. Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease. Ann Hepatol. 2025;30(2):101589.","journal-title":"Ann Hepatol"},{"key":"1332_CR9","doi-asserted-by":"publisher","DOI":"10.2147\/cia.s366255","author":"CK Kang","year":"2022","unstructured":"Kang CK, Brennan PN, Dillon JF. How to effectively monitor aging patients with chronic hepatitis B: a review. Clin Interv Aging. 2022. https:\/\/doi.org\/10.2147\/cia.s366255.","journal-title":"Clin Interv Aging"},{"issue":"11","key":"1332_CR10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","volume":"18","author":"GC Fanning","year":"2019","unstructured":"Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18(11):827\u201344.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1332_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000118","volume":"7","author":"D Bixler","year":"2023","unstructured":"Bixler D, Barker L, Lewis K, Peretz L, Teshale E. Prevalence and awareness of Hepatitis B virus infection in the United States: January 2017-March 2020. Hepatol Commun. 2023;7(4):e0118.","journal-title":"Hepatol Commun"},{"issue":"4","key":"1332_CR12","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1097\/HEP.0000000000001549","volume":"83","author":"MG Ghany","year":"2026","unstructured":"Ghany MG, Pan CQ, Lok AS, Feld JJ, Lim JK, Wang SH, et al. AASLD IDSA practice guideline on treatment of chronic hepatitis B. Hepatology. 2026;83(4):974\u201397.","journal-title":"Hepatology"},{"issue":"2","key":"1332_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298887","volume":"19","author":"DP Ladner","year":"2012","unstructured":"Ladner DP, Gmeiner M, Hasjim BJ, Mazumder N, Kang R, Parker E, et al. Increasing prevalence of cirrhosis among insured adults in the United States, 2012\u20132018. PLoS ONE. 2012;19(2):e0298887.","journal-title":"PLoS ONE"},{"issue":"3","key":"1332_CR14","first-page":"809","volume":"24","author":"L Strasfeld","year":"2010","unstructured":"Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin. 2010;24(3):809\u201333.","journal-title":"Infect Dis Clin"},{"issue":"3","key":"1332_CR15","first-page":"335","volume":"9","author":"X Ma","year":"2021","unstructured":"Ma X, Liu S, Wang M, Wang Y, Du S, Xin Y, et al. Tenofovir alafenamide fumarate, tenofovir disoproxil fumarate and entecavir: which is the most effective drug for chronic hepatitis B? A systematic review and meta-analysis. J Clin Transl Hepatol. 2021;9(3):335.","journal-title":"J Clin Transl Hepatol"},{"issue":"12","key":"1332_CR16","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","volume":"68","author":"KS Liem","year":"2019","unstructured":"Liem KS, Fung S, Wong DK, Yim C, Noureldin S, Chen J, et al. Limited sustained response after stopping nucleos (t) ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). Gut. 2019;68(12):2206\u201313.","journal-title":"Gut"},{"issue":"4","key":"1332_CR17","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","volume":"62","author":"GV Papatheodoridis","year":"2015","unstructured":"Papatheodoridis GV, Chan HL-Y, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62(4):956\u201367.","journal-title":"J Hepatol"},{"issue":"10","key":"1332_CR18","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2468-1253(25)00053-6","volume":"10","author":"PT Kennedy","year":"2025","unstructured":"Kennedy PT, Allweiss L, Bertoletti A, Cornberg M, Gehring AJ, Guidotti LG, et al. Scientific and medical evidence informing expansion of hepatitis B treatment guidelines. Lancet Gastroenterol Hepatol. 2025;10(10):941\u201351.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1332_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1546545","volume":"16","author":"CE Low","year":"2025","unstructured":"Low CE, Ge G, Yeong TJJ-M, Rana S, Loke S, Kow WC, et al. Burden of psychological symptoms and disorders among individuals with hepatitis B: a systematic review, meta-analysis and meta-regression. Front Psychiatry. 2025;16:1546545.","journal-title":"Front Psychiatry"},{"issue":"7","key":"1332_CR20","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41395-018-0093-9","volume":"113","author":"JW Shin","year":"2018","unstructured":"Shin JW, Jung SW, Lee SB, Lee BU, Park BR, Park EJ, et al. Medication nonadherence increases hepatocellular carcinoma, cirrhotic complications, and mortality in chronic hepatitis B patients treated with entecavir. Am J Gastroenterol. 2018;113(7):998\u20131008.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1332_CR21","first-page":"260","volume":"18","author":"J Luo","year":"2019","unstructured":"Luo J, You X, Chong Y, Wu Y, Gong J, Jie Y, et al. Efficacy of long-term treatment with tenofovir in Chinese nucleos (t) ide-na\u00efve chronic hepatitis B patients regardless of baseline viral load. Exp Ther Med. 2019;18(1):260\u20138.","journal-title":"Exp Ther Med"},{"issue":"1","key":"1332_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jhep.2010.06.016","volume":"54","author":"W Chotiyaputta","year":"2011","unstructured":"Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok AS. Persistence and adherence to nucleos (t) ide analogue treatment for chronic hepatitis B. J Hepatol. 2011;54(1):12\u20138.","journal-title":"J Hepatol"},{"issue":"3","key":"1332_CR23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3350\/cmh.2020.0012","volume":"26","author":"SB Lee","year":"2020","unstructured":"Lee SB, Jeong J, Park JH, Jung SW, Du Jeong I, Bang S-J, et al. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir. Clin Mol Hepatol. 2020;26(3):364.","journal-title":"Clin Mol Hepatol"},{"issue":"10","key":"1332_CR24","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/hep4.1247","volume":"2","author":"N Ford","year":"2018","unstructured":"Ford N, Scourse R, Lemoine M, Hutin Y, Bulterys M, Shubber Z, et al. Adherence to nucleos (t) ide analogue therapies for chronic hepatitis B infection: a systematic review and meta-analysis. Hepatol Commun. 2018;2(10):1160\u20137.","journal-title":"Hepatol Commun"},{"issue":"2","key":"1332_CR25","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","volume":"83","author":"European Association for The Study of The Liver","year":"2025","unstructured":"European Association for The Study of The Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502\u201383.","journal-title":"J Hepatol"},{"key":"1332_CR26","unstructured":"Centers for Medicare & Medicaid Services. Medicare Standard Analytical Files: Identifiable Data Files."},{"issue":"6","key":"1332_CR27","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1001\/jamasurg.2021.0528","volume":"156","author":"AA Ghaferi","year":"2021","unstructured":"Ghaferi AA, Schwartz TA, Pawlik TM. STROBE reporting guidelines for observational studies. JAMA Surg. 2021;156(6):577\u20138.","journal-title":"JAMA Surg"},{"issue":"7","key":"1332_CR28","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/apt.16786","volume":"55","author":"WR Kim","year":"2022","unstructured":"Kim WR, Telep LE, Jump B, Lu M, Ramroth H, Flaherty J, et al. Risk of hepatocellular carcinoma in treatment-na\u00efve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States. Aliment Pharmacol Ther. 2022;55(7):828\u201335.","journal-title":"Aliment Pharmacol Ther"},{"key":"1332_CR29","doi-asserted-by":"crossref","unstructured":"Alpern JD, Joo H, Bahr NC, Leventhal TM. Factors Associated With Adherence to First-line Antiviral Therapy Among Commercially Insured Patients With Chronic Hepatitis B. Open Forum Infectious Diseases; 2023: Oxford University Press US; 2023. p. ofad118.","DOI":"10.1093\/ofid\/ofad118"},{"issue":"9","key":"1332_CR30","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/MLR.0b013e3182984c1f","volume":"51","author":"JM Franklin","year":"2013","unstructured":"Franklin JM, Shrank WH, Pakes J, Sanf\u00e9lix-Gimeno G, Matlin OS, Brennan TA, et al. Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. Med Care. 2013;51(9):789\u201396.","journal-title":"Med Care"},{"key":"1332_CR31","doi-asserted-by":"publisher","DOI":"10.2307\/2137284","author":"RM Andersen","year":"1995","unstructured":"Andersen RM. Revisiting the behavioral model and access to medical care: does it matter. J Health Soc Behav. 1995. https:\/\/doi.org\/10.2307\/2137284.","journal-title":"J Health Soc Behav"},{"key":"1332_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199801000-00004","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998. https:\/\/doi.org\/10.1097\/00005650-199801000-00004.","journal-title":"Med Care"},{"issue":"6","key":"1332_CR33","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/gerona\/glz224","volume":"75","author":"DH Kim","year":"2020","unstructured":"Kim DH, Patorno E, Pawar A, Lee H, Schneeweiss S, Glynn RJ. Measuring frailty in administrative claims data: comparative performance of four claims-based frailty measures in the US Medicare data. J Gerontol A Biol Sci Med Sci. 2020;75(6):1120\u20135.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"28","key":"1332_CR34","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u201379.","journal-title":"Stat Med"},{"issue":"19","key":"1332_CR35","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/sim.5753","volume":"32","author":"DF McCaffrey","year":"2013","unstructured":"McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013;32(19):3388\u2013414.","journal-title":"Stat Med"},{"issue":"3","key":"1332_CR36","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0049124101029003005","volume":"29","author":"BL Jones","year":"2001","unstructured":"Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res. 2001;29(3):374\u201393.","journal-title":"Sociol Methods Res."},{"key":"1332_CR37","unstructured":"Pharmacy Quality Alliance. Adherence measures [Internet]. Alexandria (VA): Pharmacy Quality Alliance; [cited 2026 Jan 26]. Available from: https:\/\/www.pqaalliance.org\/adherence-measures"},{"issue":"1","key":"1332_CR38","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","volume":"6","author":"DS Nagin","year":"2010","unstructured":"Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6(1):109\u201338.","journal-title":"Annu Rev Clin Psychol"},{"key":"1332_CR39","unstructured":"SAS Institute Inc. SAS. 9.4 ed. Cary, NC: SAS Institute Inc.; 2013."},{"key":"1332_CR40","volume":"8","author":"L Roade","year":"2021","unstructured":"Roade L, Riveiro-Barciela M, Esteban R, Buti M. Long-term efficacy and safety of nucleos (t) ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis. 2021;8:2049936120985954.","journal-title":"Ther Adv Infect Dis"},{"issue":"8","key":"1332_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.70055","volume":"32","author":"S Anderson","year":"2025","unstructured":"Anderson S, Gielen V, Coutinho AD, Clark L, Bell C, Salehi S, et al. Duration of nucleos (t) ide analogue treatments in patients with chronic Hepatitis B virus infection in the United States. J Viral Hepat. 2025;32(8):e70055.","journal-title":"J Viral Hepat"},{"issue":"5","key":"1332_CR42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3851\/IMP3219","volume":"23","author":"S Sheppard-Law","year":"2018","unstructured":"Sheppard-Law S, Zablotska-Manos I, Kermeen M, Holdaway S, Lee A, George J, et al. Factors associated with non-adherence to HBV antiviral therapy. Antivir Ther. 2018;23(5):425\u201333.","journal-title":"Antivir Ther"},{"issue":"3","key":"1332_CR43","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/agm2.12045","volume":"1","author":"A Smaje","year":"2018","unstructured":"Smaje A, Weston\u2010Clark M, Raj R, Orlu M, Davis D, Rawle M. Factors associated with medication adherence in older patients: a systematic review. Aging Med. 2018;1(3):254\u201366.","journal-title":"Aging Med"},{"key":"1332_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e38485","author":"L Zhang","year":"2024","unstructured":"Zhang L, Tian J, Xu D, Liu Y, Zhang Z. Trajectory and predictors of adherence to nucleos (t) ide analogues medication among patients with chronic hepatitis B. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38485.","journal-title":"Heliyon"},{"issue":"4","key":"1332_CR45","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","volume":"64","author":"G Papatheodoridis","year":"2016","unstructured":"Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64(4):800\u20136.","journal-title":"J Hepatol"},{"key":"1332_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101312","author":"MX Fu","year":"2025","unstructured":"Fu MX, Lambert G, Cook A, Ndow G, Haddadin Y, Shimakawa Y, et al. Quality of life in patients with HBV infection: a systematic review and meta-analysis. JHEP Rep. 2025. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101312.","journal-title":"JHEP Rep"},{"issue":"1","key":"1332_CR47","first-page":"63","volume":"43","author":"S Ju","year":"2025","unstructured":"Ju S, Katsumata M, Mizukami A, Abersone I, Gielen V. Chronic hepatitis B costs and healthcare resource utilization in a Japanese patient population: a retrospective cross-sectional analysis. Dig Dis. 2025;43(1):63\u201374.","journal-title":"Dig Dis"},{"issue":"1","key":"1332_CR48","doi-asserted-by":"publisher","first-page":"e2144521","DOI":"10.1001\/jamanetworkopen.2021.44521","volume":"5","author":"JD Alpern","year":"2014","unstructured":"Alpern JD, Joo H, Link B, Ciaccia A, Stauffer WM, Bahr NC, et al. Trends in pricing and out-of-pocket spending on entecavir among commercially insured patients, 2014-2018. JAMA Netw Open. 2014;5(1):e2144521.","journal-title":"JAMA Netw Open"},{"key":"1332_CR49","doi-asserted-by":"crossref","unstructured":"Ma GX, Zhu L, Lu W, Handorf E, Tan Y, Yeh M-C, et al. Improving long-term adherence to monitoring\/treatment in underserved Asian Americans with chronic hepatitis B (CHB) through a multicomponent culturally tailored intervention: a randomized controlled trial. Healthcare; 2022: MDPI; 2022. p. 1944.","DOI":"10.3390\/healthcare10101944"},{"issue":"5","key":"1332_CR50","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/MEG.0000000000001558","volume":"32","author":"S Manolakopoulos","year":"2020","unstructured":"Manolakopoulos S, Striki A, Papastergiou V, Perlepe N, Zisimopoulos K, Papazoglou A, et al. Persistence and adherence to nucleos (t) ide analogues in chronic hepatitis B: a multicenter cohort study. Eur J Gastroenterol Hepatol. 2020;32(5):635\u201341.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"11","key":"1332_CR51","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1016\/j.pec.2022.06.013","volume":"105","author":"M Papus","year":"2022","unstructured":"Papus M, Dima AL, Viprey M, Schott A-M, Schneider MP, Novais T. Motivational interviewing to support medication adherence in adults with chronic conditions: systematic review of randomized controlled trials. Patient Educ Couns. 2022;105(11):3186\u2013203.","journal-title":"Patient Educ Couns"},{"issue":"1","key":"1332_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-7658-4","volume":"19","author":"S Tran","year":"2019","unstructured":"Tran S, Bennett G, Richmond J, Nguyen T, Ryan M, Hong T, et al. \u2018Teach-back\u2019is a simple communication tool that improves disease knowledge in people with chronic hepatitis B\u2013a pilot randomized controlled study. BMC Public Health. 2019;19(1):1355.","journal-title":"BMC Public Health"},{"key":"1332_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2026.1681835","volume":"14","author":"L Zhu","year":"2026","unstructured":"Zhu L, Lu W, Liu ZE, Zhu D, Yeh M-C, Nguyen MT, et al. Effects of a culturally tailored intervention on medication adherence in Chinese and Vietnamese Americans with hepatitis B: a randomized controlled trial. Front Public Health. 2026;14:1681835.","journal-title":"Front Public Health"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01332-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-026-01332-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01332-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:53:23Z","timestamp":1792104803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-026-01332-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1332"],"URL":"https:\/\/doi.org\/10.1007\/s40266-026-01332-7","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,6]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Aparasu has received research funding from Astellas Inc., Incyte Corp., Gilead, and Novartis Inc. for projects unrelated to the current work. He also receives consulting fees from CHEORS. These financial interests have been disclosed to the University of Houston, and appropriate steps have been taken to address any potential conflicts of interest. Dr. Aparasu is an Editorial Board member of Drugs & Aging, and he was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. The other authors declare no conflicts of interest for this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the University of Houston (STUDY00005200) The requirement for informed consent was waived because the study involved a retrospective secondary analysis of Medicare claims data.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived as it is a retrospective cohort study of de-identified patients.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as this study did not include identifiable individual-level information.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that supports the findings of this study are available from the Centers for Medicare & Medicaid Services. Restrictions apply to the availability of the Medicare data due to data use agreements and other licenses for this study.","order":5,"name":"Ethics","label":"Availability of data and materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No software application was developed for this study. Statistical analyses were conducted using SAS version 9.4 and PROC TRAJ. The analytic code may be available from the corresponding author upon reasonable request, subject to institutional and data-use restrictions.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.K.: conceptualization, methodology, data curation, formal analysis, and writing of original draft. P.K.J.: Conceptualization, methodology, and final draft review. J.L: Conceptualization, methodology, formal analysis guide, and final draft review. H.C.: Conceptualization, methodology, and review of final draft. X.L.: Conceptualization, formal analysis, and review of final draft. R.R.A.: Conceptualization, methodology, supervision, writing, review, and editing. All authors reviewed and approved the final manuscript.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}